Special Issue “Novel Mechanisms of Bacterial Antibiotic Resistance and Strategies to Fight Them”
- Iron Mimetics: Gallium (Ga3+), which mimics Fe3+ but cannot undergo redox reactions, disrupts iron-dependent enzymes and siderophore-mediated uptake. Gallium compounds, including Ga-protoporphyrin IX (Figure 2b), showed efficacy against ESKAPE pathogens (Enterococcus faecium, S. aureus, Klebsiella pneumoniae, A. baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) and resistant strains, though bioavailability and nephrotoxicity remain challenges [41,42,43,44,45,46]. Nanocarrier-based delivery systems and hydrogels are being developed to improve local administration and reduce side effects [47,48,49,50,51].
- Inhibition of Siderophore Biosynthesis: In Mycobacterium tuberculosis, inhibitors targeting MbtA and MbtI enzymes have shown promising results, with 5′-O-N-salicylsulfamoyl adenosine (Sal-AMS) (Figure 2c) analogs and furan-based derivatives reducing siderophore production and bacterial growth [52,53,54,55,56,57,58,59,60,61]. Similarly, in P. aeruginosa, pyoverdine inhibitors such as 5-fluorocytosine and PvdQ-targeting compounds significantly attenuate virulence [62,63,64,65,66].
- Trojan Horse Strategy: Exploiting siderophore uptake systems to deliver antibiotics enhances intracellular penetration. Cefiderocol (Figure 2d), a catecholate siderophore–cephalosporin conjugate, has received FDA approval and demonstrated potent activity against carbapenem-resistant Gram-negative pathogens in clinical trials [67,68,69,70,71,72,73]. Artificial siderophores like the 1,3,5-N,N′,N″-Tris-(2,3-dihydroxybenzoyl)-triaminomethylbenzene (MECAM) further expand this approach, enabling conjugation with diverse antibiotics for broad-spectrum or targeted activity [74].
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Adisasmito, W.B.; Almuhairi, S.; Behravesh, C.B.; Bilivogui, P.; Bukachi, S.A.; Casas, N.; Becerra, N.C.; Charron, D.F.; Chaudhary, A.; Zanella, J.R.C.; et al. One Health Action for Health Security and Equity. Lancet 2023, 401, 530–533. [Google Scholar] [CrossRef] [PubMed]
- Furlan, B.; Sobrinos-Sanguino, M.; Sammartino, M.; Monterroso, B.; Zorrilla, S.; Lanzini, A.; Suigo, L.; Valoti, E.; Massidda, O.; Straniero, V. Targeting Bacterial Cell Division with Benzodioxane–Benzamide FtsZ Inhibitors as a Novel Strategy to Fight Gram-Positive Ovococcal Pathogens. Int. J. Mol. Sci. 2025, 26, 714. [Google Scholar] [CrossRef]
- Stelitano, G.; Cocorullo, M.; Mori, M.; Villa, S.; Meneghetti, F.; Chiarelli, L.R. Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand? Int. J. Mol. Sci. 2023, 24, 6181. [Google Scholar] [CrossRef]
- Ortiz-Miravalles, L.; Sánchez-Angulo, M.; Sanz, J.M.; Maestro, B. Drug Repositioning as a Therapeutic Strategy against Streptococcus Pneumoniae: Cell Membrane as Potential Target. Int. J. Mol. Sci. 2023, 24, 5831. [Google Scholar] [CrossRef] [PubMed]
- Martínez, M.; Rizzuto, I.; Molina, R. Knowing Our Enemy in the Antimicrobial Resistance Era: Dissecting the Molecular Basis of Bacterial Defense Systems. Int. J. Mol. Sci. 2024, 25, 4929. [Google Scholar] [CrossRef]
- Lenart-Boroń, A.; Stankiewicz, K.; Czernecka, N.; Ratajewicz, A.; Bulanda, K.; Heliasz, M.; Sosińska, D.; Dworak, K.; Ciesielska, D.; Siemińska, I.; et al. Wounds of Companion Animals as a Habitat of Antibiotic-Resistant Bacteria That Are Potentially Harmful to Humans—Phenotypic, Proteomic and Molecular Detection. Int. J. Mol. Sci. 2024, 25, 3121. [Google Scholar] [CrossRef] [PubMed]
- Bravo, A.; Moreno-Blanco, A.; Espinosa, M. One Earth: The Equilibrium between the Human and the Bacterial Worlds. Int. J. Mol. Sci. 2023, 24, 15047. [Google Scholar] [CrossRef] [PubMed]
- Zorrilla, S.; Monterroso, B.; Robles-Ramos, M.-Á.; Margolin, W.; Rivas, G. FtsZ Interactions and Biomolecular Condensates as Potential Targets for New Antibiotics. Antibiotics 2021, 10, 254. [Google Scholar] [CrossRef] [PubMed]
- Kalacheva, M.S.; Da Silva, N.R.; Boersma, A.J. Liposome-Encapsulated Escherichia coli Lysates to Reconstitute Intracellular Macromolecular Crowding Effects. ACS Synth. Biol. 2025, 14, 901–908. [Google Scholar] [CrossRef] [PubMed]
- Rivas, G.; Minton, A.P. Influence of Nonspecific Interactions on Protein Associations: Implications for Biochemistry In Vivo. Annu. Rev. Biochem. 2022, 91, 321–351. [Google Scholar] [CrossRef]
- Monterroso, B.; Margolin, W.; Boersma, A.J.; Rivas, G.; Poolman, B.; Zorrilla, S. Macromolecular Crowding, Phase Separation, and Homeostasis in the Orchestration of Bacterial Cellular Functions. Chem. Rev. 2024, 124, 1899–1949. [Google Scholar] [CrossRef]
- Suigo, L.; Monterroso, B.; Sobrinos-Sanguino, M.; Alfonso, C.; Straniero, V.; Rivas, G.; Zorrilla, S.; Valoti, E.; Margolin, W. Benzodioxane-Benzamides as Promising Inhibitors of Escherichia Coli FtsZ. Int. J. Biol. Macromol. 2023, 253, 126398. [Google Scholar] [CrossRef]
- Zakeri, B.; Lu, T.K. Synthetic Biology of Antimicrobial Discovery. ACS Synth. Biol. 2013, 2, 358–372. [Google Scholar] [CrossRef]
- Huang, S.; Zhao, S.; Zhao, H.; Wen, M.; Guo, Z. Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application. Exploration 2025, 5, e20240045. [Google Scholar] [CrossRef]
- Branda, F.; Scarpa, F. Implications of Artificial Intelligence in Addressing Antimicrobial Resistance: Innovations, Global Challenges, and Healthcare’s Future. Antibiotics 2024, 13, 502. [Google Scholar] [CrossRef]
- Arnold, A.; McLellan, S.; Stokes, J.M. How AI Can Help Us Beat AMR. Npj Antimicrob. Resist. 2025, 3, 18. [Google Scholar] [CrossRef] [PubMed]
- López-Cortés, X.A.; Manríquez-Troncoso, J.M.; Sepúlveda, A.Y.; Soto, P.S. Integrating Machine Learning with MALDI-TOF Mass Spectrometry for Rapid and Accurate Antimicrobial Resistance Detection in Clinical Pathogens. Int. J. Mol. Sci. 2025, 26, 1140. [Google Scholar] [CrossRef] [PubMed]
- Sanapalli, B.K.R.; Palit, S.; Deshpande, A.; Tokala, R.; Sigalapalli, D.K.; Sanapalli, V. Artificial Intelligence and the Discovery of Antibiotics: Reinventing with Opportunities, Challenges, and Clinical Translation. Antibiotics 2026, 15, 233. [Google Scholar] [CrossRef] [PubMed]
- Wong, F.; de la Fuente-Nunez, C.; Collins, J.J. Leveraging Artificial Intelligence in the Fight against Infectious Diseases. Science 2023, 381, 164–170. [Google Scholar] [CrossRef]
- Garcillán-Barcia, M.P.; Pluta, R.; Lorenzo-Díaz, F.; Bravo, A.; Espinosa, M. The Facts and Family Secrets of Plasmids That Replicate via the Rolling-Circle Mechanism. Microbiol. Mol. Biol. Rev. 2022, 86, e00222-20. [Google Scholar] [CrossRef] [PubMed]
- Maccaro, J. Be Mindful of Your Metaphors about Microbes. mSphere 2021, 6, e00431-21. [Google Scholar] [CrossRef]
- Cavicchioli, R.; Ripple, W.J.; Timmis, K.N.; Azam, F.; Bakken, L.R.; Baylis, M.; Behrenfeld, M.J.; Boetius, A.; Boyd, P.W.; Classen, A.T.; et al. Scientists’ Warning to Humanity: Microorganisms and Climate Change. Nat. Rev. Microbiol. 2019, 17, 569–586. [Google Scholar] [CrossRef] [PubMed]
- Hobson, C.; Chan, A.N.; Wright, G.D. The Antibiotic Resistome: A Guide for the Discovery of Natural Products as Antimicrobial Agents. Chem. Rev. 2021, 121, 3464–3494. [Google Scholar] [CrossRef] [PubMed]
- Dimitriu, T. Evolution of Horizontal Transmission in Antimicrobial Resistance Plasmids. Microbiology 2022, 168, 001214. [Google Scholar] [CrossRef] [PubMed]
- Bravo, A.; Ruiz-Cruz, S.; Alkorta, I.; Espinosa, M. When Humans Met Superbugs: Strategies to Tackle Bacterial Resistances to Antibiotics. Biomol. Concepts 2018, 9, 216–226. [Google Scholar] [CrossRef]
- Cesaro, A.; Hoffman, S.C.; Das, P.; De La Fuente-Nunez, C. Challenges and Applications of Artificial Intelligence in Infectious Diseases and Antimicrobial Resistance. npj Antimicrob. Resist. 2025, 3, 2. [Google Scholar] [CrossRef]
- Rouli, L.; Merhej, V.; Fournier, P.-E.; Raoult, D. The Bacterial Pangenome as a New Tool for Analysing Pathogenic Bacteria. New Microbes New Infect. 2015, 7, 72–85. [Google Scholar] [CrossRef]
- Sasazawa, M.; Tomares, D.T.; Childers, W.S.; Saurabh, S. Biomolecular Condensates as Stress Sensors and Modulators of Bacterial Signaling. PLoS Pathog. 2024, 20, e1012413. [Google Scholar] [CrossRef]
- Macek, B.; Forchhammer, K.; Hardouin, J.; Weber-Ban, E.; Grangeasse, C.; Mijakovic, I. Protein Post-Translational Modifications in Bacteria. Nat. Rev. Microbiol. 2019, 17, 651–664. [Google Scholar] [CrossRef]
- Czaplewski, L.; Bax, R.; Clokie, M.; Dawson, M.; Fairhead, H.; Fischetti, V.A.; Foster, S.; Gilmore, B.F.; Hancock, R.E.W.; Harper, D.; et al. Alternatives to Antibiotics—A Pipeline Portfolio Review. Lancet Infect. Dis. 2016, 16, 239–251. [Google Scholar] [CrossRef]
- Fleitas Martínez, O.; Cardoso, M.H.; Ribeiro, S.M.; Franco, O.L. Recent Advances in Anti-Virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition. Front. Cell. Infect. Microbiol. 2019, 9, 74. [Google Scholar] [CrossRef] [PubMed]
- Sargun, A.; Gerner, R.R.; Raffatellu, M.; Nolan, E.M. Harnessing Iron Acquisition Machinery to Target Enterobacteriaceae. J. Infect. Dis. 2021, 223, S307–S313. [Google Scholar] [CrossRef]
- Kramer, J.; Özkaya, Ö.; Kümmerli, R. Bacterial Siderophores in Community and Host Interactions. Nat. Rev. Microbiol. 2020, 18, 152–163. [Google Scholar] [CrossRef] [PubMed]
- Klebba, P.E.; Newton, S.M.C.; Six, D.A.; Kumar, A.; Yang, T.; Nairn, B.L.; Munger, C.; Chakravorty, S. Iron Acquisition Systems of Gram-Negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics. Chem. Rev. 2021, 121, 5193–5239. [Google Scholar] [CrossRef] [PubMed]
- Wandersman, C.; Delepelaire, P. Bacterial Iron Sources: From Siderophores to Hemophores. Annu. Rev. Microbiol. 2004, 58, 611–647. [Google Scholar] [CrossRef]
- Ang, M.T.C.; Gumbau-Brisa, R.; Allan, D.S.; McDonald, R.; Ferguson, M.J.; Holbein, B.E.; Bierenstiel, M. DIBI, a 3-Hydroxypyridin-4-One Chelator Iron-Binding Polymer with Enhanced Antimicrobial Activity. MedChemComm 2018, 9, 1206–1212. [Google Scholar] [CrossRef] [PubMed]
- Parquet, M.D.C.; Savage, K.A.; Allan, D.S.; Davidson, R.J.; Holbein, B.E. Novel Iron-Chelator DIBI Inhibits Staphylococcus Aureus Growth, Suppresses Experimental MRSA Infection in Mice and Enhances the Activities of Diverse Antibiotics in Vitro. Front. Microbiol. 2018, 9, 1811. [Google Scholar] [CrossRef]
- Allan, D.S.; Parquet, M.D.C.; Savage, K.A.; Holbein, B.E. Iron Sequestrant DIBI, a Potential Alternative for Nares Decolonization of Methicillin-Resistant Staphylococcus Aureus, Is Anti-Infective and Inhibitory for Mupirocin-Resistant Isolates. Antimicrob. Agents Chemother. 2020, 64, e02353-19. [Google Scholar] [CrossRef]
- Nocera, F.P.; Iovane, G.; De Martino, L.; Holbein, B.E. Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-Susceptible Staphylococcus Pseudintermedius: A Preliminary Study of Four Clinical Strains. Pathogens 2022, 11, 656. [Google Scholar] [CrossRef] [PubMed]
- Parquet, M.D.C.; Savage, K.A.; Allan, D.S.; Ang, M.T.C.; Chen, W.; Logan, S.M.; Holbein, B.E. Antibiotic-Resistant Acinetobacter baumannii Is Susceptible to the Novel Iron-Sequestering Anti-Infective DIBI In Vitro and in Experimental Pneumonia in Mice. Antimicrob. Agents Chemother. 2019, 63, e00855-19. [Google Scholar] [CrossRef] [PubMed]
- Chitambar, C.R. Gallium and Its Competing Roles with Iron in Biological Systems. Biochim. Biophys. Acta BBA-Mol. Cell Res. 2016, 1863, 2044–2053. [Google Scholar] [CrossRef] [PubMed]
- Chitambar, C.R. The Therapeutic Potential of Iron-Targeting Gallium Compounds in Human Disease: From Basic Research to Clinical Application. Pharmacol. Res. 2017, 115, 56–64. [Google Scholar] [CrossRef]
- Choi, S.; Switzer, B.; Britigan, B.E.; Narayanasamy, P. Gallium Porphyrin and Gallium Nitrate Synergistically Inhibit Mycobacterial Species by Targeting Different Aspects of Iron/Heme Metabolism. ACS Infect. Dis. 2020, 6, 2582–2591. [Google Scholar] [CrossRef]
- Hijazi, S.; Visaggio, D.; Pirolo, M.; Frangipani, E.; Bernstein, L.; Visca, P. Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens. Front. Cell. Infect. Microbiol. 2018, 8, 316. [Google Scholar] [CrossRef] [PubMed]
- Goss, C.H.; Kaneko, Y.; Khuu, L.; Anderson, G.D.; Ravishankar, S.; Aitken, M.L.; Lechtzin, N.; Zhou, G.; Czyz, D.M.; McLean, K.; et al. Gallium Disrupts Bacterial Iron Metabolism and Has Therapeutic Effects in Mice and Humans with Lung Infections. Sci. Transl. Med. 2018, 10, eaat7520. [Google Scholar] [CrossRef]
- Mitidieri, E.; Visaggio, D.; Frangipani, E.; Turnaturi, C.; Vanacore, D.; Provenzano, R.; Costabile, G.; Sorrentino, R.; Ungaro, F.; Visca, P.; et al. Intra-Tracheal Administration Increases Gallium Availability in Lung: Implications for Antibacterial Chemotherapy. Pharmacol. Res. 2021, 170, 105698. [Google Scholar] [CrossRef] [PubMed]
- Choi, S.; Britigan, B.E.; Narayanasamy, P. Iron/Heme Metabolism-Targeted Gallium(III) Nanoparticles Are Active against Extracellular and Intracellular Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother. 2019, 63, e02643-18. [Google Scholar] [CrossRef] [PubMed]
- Choi, S.-R.; Talmon, G.A.; Britigan, B.E.; Narayanasamy, P. Nanoparticulate β-Cyclodextrin with Gallium Tetraphenylporphyrin Demonstrates in Vitro and in Vivo Antimicrobial Efficacy against Mycobacteroides abscessus and Mycobacterium avium. ACS Infect. Dis. 2021, 7, 2299–2309. [Google Scholar] [CrossRef] [PubMed]
- Richter, K.; Thomas, N.; Claeys, J.; McGuane, J.; Prestidge, C.A.; Coenye, T.; Wormald, P.-J.; Vreugde, S. A Topical Hydrogel with Deferiprone and Gallium-Protoporphyrin Targets Bacterial Iron Metabolism and Has Antibiofilm Activity. Antimicrob. Agents Chemother. 2017, 61, e00481-17. [Google Scholar] [CrossRef]
- Zheng, H.; Huang, Z.; Chen, T.; Sun, Y.; Chen, S.; Bu, G.; Guan, H. Gallium Ions Incorporated Silk Fibroin Hydrogel with Antibacterial Efficacy for Promoting Healing of Pseudomonas Aeruginosa-Infected Wound. Front. Chem. 2022, 10, 1017548. [Google Scholar] [CrossRef] [PubMed]
- Qin, J.; Li, M.; Yuan, M.; Shi, X.; Song, J.; He, Y.; Mao, H.; Kong, D.; Gu, Z. Gallium(III)-Mediated Dual-Cross-Linked Alginate Hydrogels with Antibacterial Properties for Promoting Infected Wound Healing. ACS Appl. Mater. Interfaces 2022, 14, 22426–22442. [Google Scholar] [CrossRef] [PubMed]
- Shyam, M.; Shilkar, D.; Verma, H.; Dev, A.; Sinha, B.N.; Brucoli, F.; Bhakta, S.; Jayaprakash, V. The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis. J. Med. Chem. 2021, 64, 71–100. [Google Scholar] [CrossRef]
- De Voss, J.J.; Rutter, K.; Schroeder, B.G.; Su, H.; Zhu, Y.; Barry, C.E. The Salicylate-Derived Mycobactin Siderophores of Mycobacterium tuberculosis Are Essential for Growth in Macrophages. Proc. Natl. Acad. Sci. USA 2000, 97, 1252–1257. [Google Scholar] [CrossRef] [PubMed]
- Ferreras, J.A.; Ryu, J.-S.; Di Lello, F.; Tan, D.S.; Quadri, L.E.N. Small-Molecule Inhibition of Siderophore Biosynthesis in Mycobacterium Tuberculosis and Yersinia Pestis. Nat. Chem. Biol. 2005, 1, 29–32. [Google Scholar] [CrossRef] [PubMed]
- Lun, S.; Guo, H.; Adamson, J.; Cisar, J.S.; Davis, T.D.; Chavadi, S.S.; Warren, J.D.; Quadri, L.E.N.; Tan, D.S.; Bishai, W.R. Pharmacokinetic and In Vivo Efficacy Studies of the Mycobactin Biosynthesis Inhibitor Salicyl-AMS in Mice. Antimicrob. Agents Chemother. 2013, 57, 5138–5140. [Google Scholar] [CrossRef]
- Chiarelli, L.R.; Mori, M.; Barlocco, D.; Beretta, G.; Gelain, A.; Pini, E.; Porcino, M.; Mori, G.; Stelitano, G.; Costantino, L.; et al. Discovery and Development of Novel Salicylate Synthase (MbtI) Furanic Inhibitors as Antitubercular Agents. Eur. J. Med. Chem. 2018, 155, 754–763. [Google Scholar] [CrossRef]
- Chiarelli, L.R.; Mori, M.; Beretta, G.; Gelain, A.; Pini, E.; Sammartino, J.C.; Stelitano, G.; Barlocco, D.; Costantino, L.; Lapillo, M.; et al. New Insight into Structure-Activity of Furan-Based Salicylate Synthase (MbtI) Inhibitors as Potential Antitubercular Agents. J. Enzym. Inhib. Med. Chem. 2019, 34, 823–828. [Google Scholar] [CrossRef] [PubMed]
- Mori, M.; Stelitano, G.; Gelain, A.; Pini, E.; Chiarelli, L.R.; Sammartino, J.C.; Poli, G.; Tuccinardi, T.; Beretta, G.; Porta, A.; et al. Shedding X-Ray Light on the Role of Magnesium in the Activity of Mycobacterium tuberculosis Salicylate Synthase (MbtI) for Drug Design. J. Med. Chem. 2020, 63, 7066–7080. [Google Scholar] [CrossRef] [PubMed]
- Mori, M.; Stelitano, G.; Chiarelli, L.R.; Cazzaniga, G.; Gelain, A.; Barlocco, D.; Pini, E.; Meneghetti, F.; Villa, S. Synthesis, Characterization, and Biological Evaluation of New Derivatives Targeting MbtI as Antitubercular Agents. Pharmaceuticals 2021, 14, 155. [Google Scholar] [CrossRef]
- Mori, M.; Stelitano, G.; Griego, A.; Chiarelli, L.R.; Cazzaniga, G.; Gelain, A.; Pini, E.; Camera, M.; Canzano, P.; Fumagalli, A.; et al. Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections. Pharmaceuticals 2022, 15, 992. [Google Scholar] [CrossRef] [PubMed]
- Mori, M.; Stelitano, G.; Cazzaniga, G.; Gelain, A.; Tresoldi, A.; Cocorullo, M.; Roversi, M.; Chiarelli, L.R.; Tomaiuolo, M.; Delre, P.; et al. Targeting Siderophore-Mediated Iron Uptake in M. Abscessus: A New Strategy to Limit the Virulence of Non-Tuberculous Mycobacteria. Pharmaceutics 2023, 15, 502. [Google Scholar] [CrossRef] [PubMed]
- Imperi, F.; Massai, F.; Facchini, M.; Frangipani, E.; Visaggio, D.; Leoni, L.; Bragonzi, A.; Visca, P. Repurposing the Antimycotic Drug Flucytosine for Suppression of Pseudomonas aeruginosa Pathogenicity. Proc. Natl. Acad. Sci. USA 2013, 110, 7458–7463. [Google Scholar] [CrossRef]
- Ringel, M.T.; Brüser, T. The Biosynthesis of Pyoverdines. Microb. Cell 2018, 5, 424–437. [Google Scholar] [CrossRef] [PubMed]
- Wibowo, J.P.; Batista, F.A.; Van Oosterwijk, N.; Groves, M.R.; Dekker, F.J.; Quax, W.J. A Novel Mechanism of Inhibition by Phenylthiourea on PvdP, a Tyrosinase Synthesizing Pyoverdine of Pseudomonas Aeruginosa. Int. J. Biol. Macromol. 2020, 146, 212–221. [Google Scholar] [CrossRef] [PubMed]
- Wurst, J.M.; Drake, E.J.; Theriault, J.R.; Jewett, I.T.; VerPlank, L.; Perez, J.R.; Dandapani, S.; Palmer, M.; Moskowitz, S.M.; Schreiber, S.L.; et al. Identification of Inhibitors of PvdQ, an Enzyme Involved in the Synthesis of the Siderophore Pyoverdine. ACS Chem. Biol. 2014, 9, 1536–1544. [Google Scholar] [CrossRef] [PubMed]
- Clevenger, K.D.; Wu, R.; Liu, D.; Fast, W. N-Alkylboronic Acid Inhibitors Reveal Determinants of Ligand Specificity in the Quorum-Quenching and Siderophore Biosynthetic Enzyme PvdQ. Biochemistry 2014, 53, 6679–6686. [Google Scholar] [CrossRef]
- Aoki, T.; Yoshizawa, H.; Yamawaki, K.; Yokoo, K.; Sato, J.; Hisakawa, S.; Hasegawa, Y.; Kusano, H.; Sano, M.; Sugimoto, H.; et al. Cefiderocol (S-649266), A New Siderophore Cephalosporin Exhibiting Potent Activities against Pseudomonas Aeruginosa and Other Gram-Negative Pathogens Including Multi-Drug Resistant Bacteria: Structure Activity Relationship. Eur. J. Med. Chem. 2018, 155, 847–868. [Google Scholar] [CrossRef] [PubMed]
- Zalas-Więcek, P.; Płachta, K.; Gospodarek-Komkowska, E. Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia Coli: An In Vitro Study in Poland. Pathogens 2022, 11, 1508. [Google Scholar] [CrossRef]
- Kaye, K.S.; Naas, T.; Pogue, J.M.; Rossolini, G.M. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales. Infect. Dis. Ther. 2023, 12, 777–806. [Google Scholar] [CrossRef] [PubMed]
- Burnard, D.; Robertson, G.; Henderson, A.; Falconer, C.; Bauer, M.J.; Cottrell, K.; Gassiep, I.; Norton, R.; Paterson, D.L.; Harris, P.N.A. Burkholderia Pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin. Antimicrob. Agents Chemother. 2021, 65, e00685-20. [Google Scholar] [CrossRef]
- Saisho, Y.; Katsube, T.; White, S.; Fukase, H.; Shimada, J. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects. Antimicrob. Agents Chemother. 2018, 62, e02163-17. [Google Scholar] [CrossRef]
- Wu, J.Y.; Srinivas, P.; Pogue, J.M. Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms. Infect. Dis. Ther. 2020, 9, 17–40. [Google Scholar] [CrossRef]
- Wunderink, R.G.; Matsunaga, Y.; Ariyasu, M.; Clevenbergh, P.; Echols, R.; Kaye, K.S.; Kollef, M.; Menon, A.; Pogue, J.M.; Shorr, A.F.; et al. Cefiderocol versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial. Lancet Infect. Dis. 2021, 21, 213–225. [Google Scholar] [CrossRef]
- Pinkert, L.; Lai, Y.-H.; Peukert, C.; Hotop, S.-K.; Karge, B.; Schulze, L.M.; Grunenberg, J.; Brönstrup, M. Antibiotic Conjugates with an Artificial MECAM-Based Siderophore Are Potent Agents against Gram-Positive and Gram-Negative Bacterial Pathogens. J. Med. Chem. 2021, 64, 15440–15460. [Google Scholar] [CrossRef] [PubMed]
- Marner, M.; Kolberg, L.; Horst, J.; Böhringer, N.; Hübner, J.; Kresna, I.D.M.; Liu, Y.; Mettal, U.; Wang, L.; Meyer-Bühn, M.; et al. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas Aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients. Microbiol. Spectr. 2023, 11, e04437-22. [Google Scholar] [CrossRef] [PubMed]
- Rostøl, J.T.; Marraffini, L. (Ph)Ighting Phages: How Bacteria Resist Their Parasites. Cell Host Microbe 2019, 25, 184–194. [Google Scholar] [CrossRef]
- Tal, N.; Sorek, R. SnapShot: Bacterial Immunity. Cell 2022, 185, 578–578.e1. [Google Scholar] [CrossRef] [PubMed]
- Tesson, F.; Hervé, A.; Mordret, E.; Touchon, M.; d’Humières, C.; Cury, J.; Bernheim, A. Systematic and Quantitative View of the Antiviral Arsenal of Prokaryotes. Nat. Commun. 2022, 13, 2561. [Google Scholar] [CrossRef]
- Roberts, R.J.; Vincze, T.; Posfai, J.; Macelis, D. REBASE: A Database for DNA Restriction and Modification: Enzymes, Genes and Genomes. Nucleic Acids Res. 2023, 51, D629–D630. [Google Scholar] [CrossRef]
- Hille, F.; Richter, H.; Wong, S.P.; Bratovič, M.; Ressel, S.; Charpentier, E. The Biology of CRISPR-Cas: Backward and Forward. Cell 2018, 172, 1239–1259. [Google Scholar] [CrossRef]
- Cheng, R.; Huang, F.; Wu, H.; Lu, X.; Yan, Y.; Yu, B.; Wang, X.; Zhu, B. A Nucleotide-Sensing Endonuclease from the Gabija Bacterial Defense System. Nucleic Acids Res. 2021, 49, 5216–5229. [Google Scholar] [CrossRef]
- Athukoralage, J.S.; White, M.F. Cyclic Nucleotide Signaling in Phage Defense and Counter-Defense. Annu. Rev. Virol. 2022, 9, 451–468. [Google Scholar] [CrossRef]
- Simon, A.J.; Ellington, A.D.; Finkelstein, I.J. Retrons and Their Applications in Genome Engineering. Nucleic Acids Res. 2019, 47, 11007–11019. [Google Scholar] [CrossRef]
- Millman, A.; Melamed, S.; Leavitt, A.; Doron, S.; Bernheim, A.; Hör, J.; Garb, J.; Bechon, N.; Brandis, A.; Lopatina, A.; et al. An Expanded Arsenal of Immune Systems That Protect Bacteria from Phages. Cell Host Microbe 2022, 30, 1556–1569.e5. [Google Scholar] [CrossRef] [PubMed]
- LeRoux, M.; Laub, M.T. Toxin-Antitoxin Systems as Phage Defense Elements. Annu. Rev. Microbiol. 2022, 76, 21–43. [Google Scholar] [CrossRef] [PubMed]
- Zeng, Z.; Chen, Y.; Pinilla-Redondo, R.; Shah, S.A.; Zhao, F.; Wang, C.; Hu, Z.; Wu, C.; Zhang, C.; Whitaker, R.J.; et al. A Short Prokaryotic Argonaute Activates Membrane Effector to Confer Antiviral Defense. Cell Host Microbe 2022, 30, 930–943.e6. [Google Scholar] [CrossRef] [PubMed]
- WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 4 February 2026).
- Walsh, C.T.; Wencewicz, T.A. Prospects for New Antibiotics: A Molecule-Centered Perspective. J. Antibiot. 2014, 67, 7–22. [Google Scholar] [CrossRef]
- Fischbach, M.A.; Walsh, C.T. Antibiotics for Emerging Pathogens. Science 2009, 325, 1089–1093. [Google Scholar] [CrossRef] [PubMed]
- Silver, L.L. Challenges of Antibacterial Discovery. Clin. Microbiol. Rev. 2011, 24, 71–109. [Google Scholar] [CrossRef]
- Erickson, H.P.; Anderson, D.E.; Osawa, M. FtsZ in Bacterial Cytokinesis: Cytoskeleton and Force Generator All in One. Microbiol. Mol. Biol. Rev. 2010, 74, 504–528. [Google Scholar] [CrossRef]
- Kusuma, K.D.; Payne, M.; Ung, A.T.; Bottomley, A.L.; Harry, E.J. FtsZ as an Antibacterial Target: Status and Guidelines for Progressing This Avenue. ACS Infect. Dis. 2019, 5, 1279–1294. [Google Scholar] [CrossRef] [PubMed]
- Araujo-Bazan, L.; Ruiz-Avila, L.B.; Andreu, D.; Huecas, S.; Andreu, J.M. Cytological Profile of Antibacterial FtsZ Inhibitors and Synthetic Peptide MciZ. Front. Microbiol. 2016, 7, 1558. [Google Scholar] [CrossRef]
- Casiraghi, A.; Suigo, L.; Valoti, E.; Straniero, V. Targeting Bacterial Cell Division: A Binding Site-Centered Approach to the Most Promising Inhibitors of the Essential Protein FtsZ. Antibiotics 2020, 9, 69. [Google Scholar] [CrossRef] [PubMed]
- Straniero, V.; Sebastián-Pérez, V.; Hrast, M.; Zanotto, C.; Casiraghi, A.; Suigo, L.; Zdovc, I.; Radaelli, A.; De Giuli Morghen, C.; Valoti, E. Benzodioxane-Benzamides as Antibacterial Agents: Computational and SAR Studies to Evaluate the Influence of the 7-Substitution in FtsZ Interaction. ChemMedChem 2020, 15, 195–209. [Google Scholar] [CrossRef] [PubMed]
- Suigo, L.; Margolin, W.; Ulzurrun, E.; Hrast Rambaher, M.; Zanotto, C.; Sebastián-Pérez, V.; Campillo, N.E.; Straniero, V.; Valoti, E. Benzodioxane–Benzamides as FtsZ Inhibitors: Effects of Linker’s Functionalization on Gram-Positive Antimicrobial Activity. Antibiotics 2023, 12, 1712. [Google Scholar] [CrossRef]
- Perez, A.J.; Villicana, J.B.; Tsui, H.-C.T.; Danforth, M.L.; Benedet, M.; Massidda, O.; Winkler, M.E. FtsZ-Ring Regulation and Cell Division Are Mediated by Essential EzrA and Accessory Proteins ZapA and ZapJ in Streptococcus Pneumoniae. Front. Microbiol. 2021, 12, 780864. [Google Scholar] [CrossRef]
- Straniero, V.; Suigo, L.; Casiraghi, A.; Sebastián-Pérez, V.; Hrast, M.; Zanotto, C.; Zdovc, I.; De Giuli Morghen, C.; Radaelli, A.; Valoti, E. Benzamide Derivatives Targeting the Cell Division Protein FtsZ: Modifications of the Linker and the Benzodioxane Scaffold and Their Effects on Antimicrobial Activity. Antibiotics 2020, 9, 160. [Google Scholar] [CrossRef] [PubMed]
- Vandevelde, N.M.; Tulkens, P.M.; Diaz Iglesias, Y.; Verhaegen, J.; Rodriguez-Villalobos, H.; Philippart, I.; Cadrobbi, J.; Coppens, N.; Boel, A.; Van Vaerenbergh, K.; et al. Characterisation of a Collection of Streptococcus Pneumoniae Isolates from Patients Suffering from Acute Exacerbations of Chronic Bronchitis: In Vitro Susceptibility to Antibiotics and Biofilm Formation in Relation to Antibiotic Efflux and Serotypes/Serogroups. Int. J. Antimicrob. Agents 2014, 44, 209–217. [Google Scholar] [CrossRef]
- Zhang, Z.; Chen, M.; Yu, Y.; Pan, S.; Liu, Y. Antimicrobial Susceptibility among Streptococcus Pneumoniae and Haemophilus Influenzae Collected Globally between 2015 and 2017 as Part of the Tigecycline Evaluation and Surveillance Trial (TEST). Infect. Drug Resist. 2019, 12, 1209–1220. [Google Scholar] [CrossRef]
- Wang, H.; Huebner, R.; Chen, M.; Klugman, K. Antibiotic Susceptibility Patterns of Streptococcus pneumoniae in China and Comparison of MICs by Agar Dilution and E-Test Methods. Antimicrob. Agents Chemother. 1998, 42, 2633–2636. [Google Scholar] [CrossRef]
- Pomba, C.; Rantala, M.; Greko, C.; Baptiste, K.E.; Catry, B.; Van Duijkeren, E.; Mateus, A.; Moreno, M.A.; Pyörälä, S.; Ružauskas, M.; et al. Public Health Risk of Antimicrobial Resistance Transfer from Companion Animals. J. Antimicrob. Chemother. 2017, 72, 957–968. [Google Scholar] [CrossRef] [PubMed]
- Windahl, U.; Bengtsson, B.; Nyman, A.-K.; Holst, B. The Distribution of Pathogens and Their Antimicrobial Susceptibility Patterns among Canine Surgical Wound Infections in Sweden in Relation to Different Risk Factors. Acta Vet. Scand. 2015, 57, 11. [Google Scholar] [CrossRef] [PubMed]
- Guardabassi, L.; Schwarz, S.; Lloyd, D.H. Pet Animals as Reservoirs of Antimicrobial-Resistant Bacteria: Review. J. Antimicrob. Chemother. 2004, 54, 321–332. [Google Scholar] [CrossRef]
- Alberti, S.; Dormann, D. Liquid–Liquid Phase Separation in Disease. Annu. Rev. Genet. 2019, 53, 171–194. [Google Scholar] [CrossRef]
- Ostan, N.K.H.; Cole, G.B.; Wang, F.Z.; Reichheld, S.E.; Moore, G.; Pan, C.; Yu, R.; Lai, C.C.-L.; Sharpe, S.; Lee, H.O.; et al. A Secreted Bacterial Protein Protects Bacteria from Cationic Antimicrobial Peptides by Entrapment in Phase-Separated Droplets. PNAS Nexus 2024, 3, pgae139. [Google Scholar] [CrossRef]
- Sneideris, T.; Erkamp, N.A.; Ausserwöger, H.; Saar, K.L.; Welsh, T.J.; Qian, D.; Katsuya-Gaviria, K.; Johncock, M.L.L.Y.; Krainer, G.; Borodavka, A.; et al. Targeting Nucleic Acid Phase Transitions as a Mechanism of Action for Antimicrobial Peptides. Nat. Commun. 2023, 14, 7170. [Google Scholar] [CrossRef]
- Sobrinos-Sanguino, M.; Barros-Medina, I.; Suigo, L.; Lanzini, A.; Valoti, E.; Margolin, W.; Straniero, V.; Monterroso, B.; Zorrilla, S. Benzodioxane-Benzamides Targeting Bacterial Cell Division Protein FtsZ Potentially Disrupt SlmA-Mediated Nucleoid Occlusion and Reversible Biomolecular Condensation. Int. J. Biol. Macromol. 2025, 332, 148516. [Google Scholar] [CrossRef] [PubMed]





Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Straniero, V.; Monterroso, B.; Zorrilla, S. Special Issue “Novel Mechanisms of Bacterial Antibiotic Resistance and Strategies to Fight Them”. Int. J. Mol. Sci. 2026, 27, 3432. https://doi.org/10.3390/ijms27083432
Straniero V, Monterroso B, Zorrilla S. Special Issue “Novel Mechanisms of Bacterial Antibiotic Resistance and Strategies to Fight Them”. International Journal of Molecular Sciences. 2026; 27(8):3432. https://doi.org/10.3390/ijms27083432
Chicago/Turabian StyleStraniero, Valentina, Begoña Monterroso, and Silvia Zorrilla. 2026. "Special Issue “Novel Mechanisms of Bacterial Antibiotic Resistance and Strategies to Fight Them”" International Journal of Molecular Sciences 27, no. 8: 3432. https://doi.org/10.3390/ijms27083432
APA StyleStraniero, V., Monterroso, B., & Zorrilla, S. (2026). Special Issue “Novel Mechanisms of Bacterial Antibiotic Resistance and Strategies to Fight Them”. International Journal of Molecular Sciences, 27(8), 3432. https://doi.org/10.3390/ijms27083432

